Madrigal Pharmaceuticals (MDGL) Current Assets (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Current Assets data on file, last reported at $1.2 billion in Q1 2026.

• On a quarterly basis, Current Assets rose 19.67% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 19.67% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 20.61% from the prior year.
• Current Assets for Q1 2026 stood at $1.2 billion, down from $1.2 billion in the prior quarter.
• Over the last five years, Current Assets for MDGL reached as high as $1.3 billion in Q3 2025 and fell as low as $157.1 million in Q3 2022.
• Historically, Current Assets has averaged $734.6 million across 5 years, with a median of $988.0 million in 2025.
• Across the five-year window, Current Assets plunged 48.14% in 2022 and jumped 351.72% in 2024, its largest moves.
• Year by year, Current Assets stood at $361.4 million in 2022, then surged by 76.35% to $637.3 million in 2023, then jumped by 62.08% to $1.0 billion in 2024, then gained by 20.61% to $1.2 billion in 2025, then retreated by 5.09% to $1.2 billion in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $1.2 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.3 billion in Q3 2025.